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ABSTRACT
Background To better predict response to immune 
checkpoint therapy and toxicity in healthy tissues, insight 
in the in vivo behavior of immune checkpoint targeting 
monoclonal antibodies is essential. Therefore, we aimed 
to study in vivo pharmacokinetics and whole- body 
distribution of zirconium-89 (89Zr) labeled programmed 
cell death protein-1 (PD-1) targeting pembrolizumab with 
positron- emission tomography (PET) in humanized mice.
Methods Humanized (huNOG) and non- humanized NOG 
mice were xenografted with human A375M melanoma 
cells. PET imaging was performed on day 7 post 89Zr- 
pembrolizumab (10 µg, 2.5 MBq) administration, followed 
by ex vivo biodistribution studies. Other huNOG mice 
bearing A375M tumors received a co- injection of excess 
(90 µg) unlabeled pembrolizumab or 89Zr- IgG4 control 
(10 µg, 2.5 MBq). Tumor and spleen tissue were studied 
with autoradiography and immunohistochemically 
including PD-1.
Results PET imaging and biodistribution studies showed 
high 89Zr- pembrolizumab uptake in tissues containing 
human immune cells, including spleen, lymph nodes and 
bone marrow. Tumor uptake of 89Zr- pembrolizumab was 
lower than uptake in lymphoid tissues, but higher than 
uptake in other organs. High uptake in lymphoid tissues 
could be reduced by excess unlabeled pembrolizumab. 
Tracer activity in blood pool was increased by addition 
of unlabeled pembrolizumab, but tumor uptake was not 
affected. Autoradiography supported PET findings and 
immunohistochemical staining on spleen and lymph node 
tissue showed PD-1 positive cells, whereas tumor tissue 
was PD-1 negative.
Conclusion 89Zr- pembrolizumab whole- body 
biodistribution showed high PD-1- mediated uptake in 
lymphoid tissues, such as spleen, lymph nodes and bone 
marrow, and modest tumor uptake. Our data may enable 
evaluation of 89Zr- pembrolizumab whole- body distribution 
in patients.
BACKGROUND
Immune checkpoint inhibitors targeting the 
programmed cell death protein-1 (PD-1/
programmed death ligand-1 (PD- L1) 
pathway are showing impressive antitumor 
effects. However, not all patients respond 
and serious immune- related toxicity has 
been reported.1 This has raised interest in 
better understanding the behavior of these 
drugs in the human body. PD- L1 and PD-1 
are expressed by a broad range of immune 
cells, including T- cells, B- cells, natural killer 
(NK) cells, monocytes and dendritic cells. 
PD- L1 can be highly expressed by tumor cells, 
whereas PD-1 expression is most prominent 
in T- cells and lower in other immune cells.2 
Biodistribution of PD-1 and PD- L1 targeting 
drugs will likely be influenced by the dynamic 
expression patterns of these targets.
Molecular imaging has proven to be an 
useful tool for studying drug biodistribu-
tion.3 4 In table 1, we summarized preclinical 
imaging studies that investigated biodistribu-
tion of radiolabeled molecules targeting PD-1 
and PD- L1.5–28 Most studies that we reviewed 
focused on tracer distribution in the tumor 
and its microenvironment, without consid-
ering PD-1 and PD- L1 expression in healthy 
immune tissues. Studies that do report on 
tracer uptake in lymphoid tissues are scarce 
and results are often limited to the spleen. 
Furthermore, most tracers targeting human 
PD-1/PD- L1 are not cross- reactive with murine 
proteins and relevant mouse models reconsti-
tuted with (parts of) a human immune system 
are rarely used. A limited number of studies 
used NOD scid gamma (NSG) mice engrafted 
with human peripheral blood mononuclear 
cells (hNSG model).23–25 27 The hNSG model 
has a high level of functional T- cells, however, 
it is also characterized by aberrant distribution 
of immune cells to murine immune tissues 
and other cell lineages remain underdevel-
oped.29 Humanized mice that are engrafted 
with human CD34 + hematopoietic stem cells 
(HSCs) establish an immune- competent 
model with a broader set of developed human 
immune cells present and might therefore be 
a better surrogate for the human immune 
environment.
To gain more insight in the in vivo behavior 
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antibody (mAb), not cross- reactive with murine PD-1, we 
aimed to study the biodistribution of zirconium-89 (89Zr) 
radiolabeled pembrolizumab in melanoma- bearing 
humanized NOG mice (huNOG) engrafted with HSCs 
using positron- emission tomography (PET) imaging. To 
enable consecutive clinical translation of this approach, 
we developed and validated a good manufacturing prac-
tices (GMP) compliant production process for 89Zr- pem-
brolizumab. Finally, we put our data in perspective by 
summarizing results from current in vivo preclinical 




The human melanoma cell line A375M was purchased 
from the American Type Culture Collection. Cell lines 
were confirmed to be negative for microbial contamina-
tion and were authenticated on August 6, 2018, by Base-
Clear using short tandem repeat profiling. A375M cells 
were routinely cultured in Roswell Park Memorial Insti-
tute 1640 medium (Invitrogen) containing 10% fetal calf 
serum (Bodinco BV), under humidified conditions at 
37°C with 5% CO2. Cells were passaged 1:10, twice a week. 
For in vivo experiments, cells in the exponential growth 
phase were used.
Development of 89Zr-pembrolizumab and 89Zr-IgG4
First, the buffer of pembrolizumab (25 mg/mL, Merck) 
was exchanged for NaCl 0.9% (Braun) using a Vivaspin-2 
concentrator (30 kDa) with a polyethersulfon filter 
(Sartorius). Next, pembrolizumab was conjugated with 
the tetrafluorphenol- N- succinyldesferal- Fe(III) ester 
(TFP- N- sucDf; ABX) as described earlier, in a 1:2 TFP- N- 
sucDf:mAb ratio.30 Conjugated product was purified from 
unbound chelator using Vivaspin-2 concentrators and 
stored at −80 °C. On the day of tracer injection, N- sucDf- 
pembrolizumab was radiolabeled with 89Zr, delivered 
as 89Zr- oxalate dissolved in oxalic acid (PerkinElmer), 
as described previously.30 For in vivo studies, pembroli-
zumab was radiolabeled at a specific activity of 250 MBq/
mg. IgG4 control molecule (Sigma- Aldrich) was conju-
gated with TFP- N- sucDf at a 1:3 molar ratio, followed by 
radiolabeling with 89Zr at similar specific activity of 250 
MBq/mg.
Quality control of 89Zr-pembrolizumab
Size exclusion high- performance liquid chromatography 
(SE- HPLC) was used to determine the final number of TFP- 
N- sucDf ligands per antibody (chelation ratio). SE- HPLC 
analysis was also performed to assess potential aggrega-
tion and fragmentation for both N- sucDf- pembrolizumab 
and 89Zr- pembrolizumab. An HPLC system (Waters) 
equipped with an isocratic pump (Waters), a dual wave-
length absorbance detector (Waters), in- line radioactivity 
detector (Berthold) and a TSK- GEL G3000SWXL column 
(Tosoh Biosciences) was used with phosphate buffered 
saline (PBS, sodium chloride 140.0 mmol/L, sodium 
hydrogen phosphate 0.9 mmol/L, sodium dihydrogen 
phosphate 1.3 mmol/L; pH 7.4) as mobile phase (flow 
0.7 mL/min). Radiochemical purity of 89Zr- pembroli-
zumab was measured by trichloroacetic acid precipita-
tion assay.31 Immunoreactivity of 89Zr- pembrolizumab was 
analyzed by a competition binding assay with unlabeled 
pembrolizumab. Nunc- immuno break apart 96- wells 
plates (Thermo Scientific) were coated overnight at 4°C 
with 100 µL of 1 µg/mL PD-1 extracellular domain (R&D 
Systems) in PBS, set to pH 9.6 with Na2CO3 2M. Plates 
were washed with 0.1% Tween 80 in PBS and blocked for 
1 hour at room temperature (RT) with 150 µL 1% human 
serum albumin (Albuman, Sanquin) in PBS. Multiple 1:1 
mixtures of 89Zr- pembrolizumab with unlabeled pembroli-
zumab were prepared, using a fixed concentration of 
89Zr- pembrolizumab (7000 ng/mL) and varying concen-
trations of unlabeled pembrolizumab (from 3.75 ng/mL 
to 12.5×106 ng/mL). Of each mixture, 100 µL was added 
to the 96- wells plate and incubated for 2 hours at RT. After 
washing twice with washing buffer, radioactivity in each 
well was counted using a gamma counter (Wizard2 2480–
0019, SW 2.1, PerkinElmer). Counts were plotted against 
the concentration of competing unlabeled pembroli-
zumab. The half maximal inhibitory concentration (IC50) 
was calculated using GraphPad Prism 7 (GraphPad soft-
ware). Immunoreactivity was expressed as the IC50 value 
divided by the 89Zr- pembrolizumab concentration to 
calculate the immune reactive fraction (IRF).
Animal studies
All animal studies were approved by the Institutional 
Animal Care and Use Committee of the University of 
Groningen. Studies were performed in humanized NOG 
mice (NOD.Cg- Prkdcscid Il2rgtm1Sug/JicTac, Taconic) and 
non- humanized NOG mice (Taconic) were used for 
control experiments. HuNOG mice are sublethally irra-
diated 3 weeks after birth and subsequently reconstituted 
with human CD34+ hematopoietic stem cells derived from 
fetal cord blood to express a functional human immune 
system including B- cells, T- cells, NK- cells, dendritic cells 
and monocytes. HuNOG and NOG mice were subcutane-
ously xenografted with 5×106 A375M human melanoma 
cells in 300 µL of a 1:1 mixture of PBS and Matrigel (BD 
Biosciences) on the right flank. Tumor growth was assessed 
by caliper measurements. When tumor volumes reached 
100 to 200 mm3 (after 2 weeks), 2.5 MBq 89Zr- pembroli-
zumab (10 µg) was administered via retro- orbital injec-
tion. Mice were anesthetized using isoflurane/medical air 
inhalation (5% induction, 2.5% maintenance).
The first group of huNOG mice received 10 µg 
89Zr- pembrolizumab (n=5). In addition, a second group 
of huNOG mice xenografted with the same tumor model 
received a co- injection of 10 µg 89Zr- pembrolizumab and 
90 µg unlabeled pembrolizumab (n=4). To a third group 
of huNOG mice, 2.5 MBq 89Zr- IgG4 control (10 µg) was 
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PET imaging and ex vivo biodistribution
On day 7 post tracer injection (pi), PET scanning was 
performed. We selected this day based on optimal tumor- 
to- blood ratio and technical aspects, including feasible 
tracer specific activity and animal welfare. Mice were 
placed in a Focus 220 rodent scanner (CTI Siemens) on 
heating matrasses. Acquisition time was 60 min. A trans-
mission scan of 515 s was performed using a 57Co point 
source to correct for tissue attenuation. After scanning, 
mice were sacrificed for ex vivo biodistribution. Bone 
marrow was collected from the femur bone by centrifugal- 
based separation. All other organs were dissected and 
counted in a gamma- counter (Wizard2 2480–0019, SW 2.1, 
PerkinElmer). Tracer uptake in each organ was expressed 
as percentage of the injected dose per gram tissue weight, 
calculated by the following formula: %ID/g = (activity 
in tissue (MBq)/total injected activity (MBq))/tissue 
weight (g)×100. To compare ex vivo and in vivo uptake, 
ex vivo uptake was also calculated as mean radioactivity 
per gram tissue, adjusted for total body weight (SUVmean ex 
vivo), calculated with the following formula: SUVmean ex vivo = 
(activity in tissue (MBq)/total injected activity (MBq))×-
mouse weight (g). Calculations are corrected for decay 
and background.
PET data was reconstructed and in vivo quantification 
was performed using PMOD software (V.4.0, PMOD tech-
nologies LCC). Three- dimensional regions of interest 
were drawn around the tumor. For other organs and 
tissues, a size- fixed sphere was drawn in representative 
tissue parts. PET data was presented as mean standardized 
uptake value (SUVmean in vivo), calculated by the following 
formula: SUVmean (g/mL) = (activity concentration (Bq/
mL)/applied dose (Bq))×weight (kg)×1000.
Autoradiography
Tumor and spleen from ex vivo biodistribution studies 
were formalin- fixed and paraffin embedded (FFPE). 
FFPE tissue blocks where cut into slices of 4 µM. These 
slices were exposed to a phosphor imaging screen (Perki-
nElmer) for 72 hours and then scanned using a Cyclone 
phosphor imager (PerkinElmer).
Immunohistochemistry
Subsequent slices of the same tumor, spleen and mesen-
teric lymph node tissue were stained for H&E, CD3, CD8 
and PD-1. FFPE tumor, spleen and lymph node tissue 
were cut into 4 µm slices using a microtome (Microm Hm 
355 s, Thermo Scientific) and mounted on glass slides. 
Tissue sections were deparaffinized and rehydrated using 
xylene and ethanol. Heat- induced antigen retrieval was 
performed in citrate buffer (pH=6) at 100°C for 15 min. 
Endogenous peroxidase was blocked by 30 min incuba-
tion with 0.3% H2O2 in PBS. For CD3 staining, slides were 
incubated with rabbit anti- human CD3- antibody (Spring 
bioscience; clone SP162) in a 1:100 dilution in PBS/1% 
bovine serum albumin (BSA) at RT for 15 min. For CD8 
staining, slides were incubated with rabbit anti- human 
CD8- antibody (Abcam; clone SP16) in a 1:50 dilution in 
PBS/1% BSA at 4°C overnight. For PD-1 staining, slides 
were incubated with rabbit anti- human PD-1- antibody 
(Abcam, clone EPR4877(2)) in a 1:500 dilution in 
PBS/1% BSA at RT for 30 min. Human tonsil or lymph 
nodes tissues sections served ad positive control and were 
incubated with either CD3, CD8 or PD-1 antibody. As a 
negative control human tonsil or lymph nodes sections 
were incubated with rabbit IgG monoclonal antibody 
(Abcam, clone EPR25A) or PBS/1% BSA.
For CD3, CD8 and PD-1 staining, incubation with 
secondary antibody (anti- rabbit EnVision+, Dako) was 
performed for 30 min, followed by application of diam-
inobenzidine chromogen for 10 min. Hematoxylin 
counterstaining was applied and tissue sections were 
dehydrated using ethanol and imbedded using mounting 
medium (Eukitt). H&E staining served to analyze tissue 
viability and morphology. Digital scans were acquired by 
a Nanozoomer 2.0- HT multi slide scanner (Hamamatsu).
89Zr-pembrolizumab manufacturing according to GMP
To enable clinical application, GMP- compliant 89Zr- pem-
brolizumab was developed. First, N- sucDf- pembrolizumab 
intermediate product was produced on a larger scale 
(60 mg batch, divided in 2.5 mg aliquots) and subse-
quently radiolabeled with 89Zr, followed by purification, 
dilution and sterile filtration (online supplemental 
figure S1). Release specifications were defined, as shown 
in online supplemental table S1. All analytical methods 
for quality control (QC) were validated. According to 
protocol validation of both N- sucDf- pembrolizumab and 
89Zr- pembrolizumab, manufacturing consisted of three 
independent validation runs, including complete release 
QC. Stability of N- sucDf- pembrolizumab stored at −80 °C 
was studied up to 6 months and stability of 89Zr- pembroli-
zumab was determined up to 168 hours at 2°C to 8°C 
stored in a sterile, type 1 glass injection vial. In addition, 
in use stability was demonstrated at RT in a polypropylene 
syringe for up to 4 hours (online supplemental table S2).
Statistical analysis
Data are presented as median±IQR. A Mann- Whitney U 
test, followed by a Bonferroni correction was performed 
to compare groups (GraphPad, Prism 7). P values ≤0.05 
were considered significant. If not indicated otherwise, 
results were not statistically significant.
RESULTS
89Zr-pembrolizumab development for in vivo studies
We optimized the conjugation processes of pembroli-
zumab with the TFP- N- sucDf chelator and its subsequent 
radiolabeling with 89Zr. For in vivo studies, N- sucDf- 
pembrolizumab was produced with >60% yield and average 
1.7 chelators per antibody (online supplemental figure 
S2, table S1). N- sucDf- pembrolizumab was subsequently 
radiolabeled with 89Zr at a specific activity of 250 MBq/
mg, with radiochemical purity of >95% after purification. 
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were stable, as shown in online supplemental table S1, 
S2 and figure S2. Immunoreactivity was not impaired by 
conjugation or radiolabeling.
89Zr-pembrolizumab imaging and biodistribution in humanized 
mice
PET imaging revealed 89Zr- pembrolizumab uptake in 
tumor, but also in healthy tissues, including liver, spleen 
and lymph nodes, of A375M tumor- bearing huNOG mice 
(figure 1A,B). Consistent with these results, ex vivo biodis-
tribution at day 7 pi showed highest 89Zr- pembrolizumab 
uptake in spleen (SUVmean 30.5, IQR 15.8 to 67.7), mesen-
teric lymph nodes (SUVmean 20.4, IQR 8.0 to 25.2), bone 
marrow (SUVmean 14.5, IQR 6.1 to 32.8), thymus (SUVmean 
1.3, IQR 1.1 to 2.1), liver (SUVmean, IQR 6.0, IQR 3.4 to 
9.9) and tumor (SUVmean 5.1, IQR 3.3 to 8.9) (figure 1C, 
online supplemental table S3).
Tumor uptake of 89Zr- pembrolizumab was variable and 
slightly higher than tumor uptake observed for 89Zr- IgG4 
control, however not significant due to small groups of 
mice (SUVmean 5.1, IQR 3.3 to 8.9 vs SUVmean 3.5, IQR 2.7 
to 4.4) (figure 1C). This may be explained by low PD-1 
expression found in all tumors by immunohistochemical 
(IHC) analysis (figure 2). 89Zr- pembrolizumab tumor- 
to- blood ratio also did not differ from 89Zr- IgG4 control 
(figure 1D).
89Zr- pembrolizumab in huNOG mice showed higher 
uptake in lymphoid tissues compared with 89Zr- IgG4 
control: spleen (SUVmean 13.9, IQR 7.1 to 21.4, NS, 
p=0.254), mesenteric lymph nodes (SUVmean 2.3, IQR 1.4 
to 4.4, NS, p=0.114), salivary gland (SUVmean 2.1, IQR 1.2 
to 2.9, NS, p=0.635), bone marrow (SUVmean 8.8, IQR 7.6 
to 10.0, NS, p=1.714) and thymus (SUVmean 0.5, IQR 0.4 
to 1.1, p=0.1714), indicating that 89Zr- pembrolizumab 
uptake in these tissues is, at least partly, PD-1- mediated. 
89Zr- pembrolizumab tissue- to- blood (T:B) and tissue- to- 
muscle (T:M) ratios in lymphoid organs confirmed high 
uptake in these tissues (figure 1D,E). Additionally, rela-
tively high 89Zr- IgG4 uptake was found in spleen, bone 
marrow and liver compared with other organs, suggesting 
89Zr- pembrolizumab uptake in these tissues is also due 
to Fcγ receptor (FcγR)- binding of the antibody’s Fc- tail. 
High 89Zr- IgG4 uptake was less evident in lymph nodes 
and thymus.
Figure 1 In vivo PET imaging and ex vivo biodistribution of 89Zr- pembrolizumab in immunocompetent humanized NOG 
mice. Mice were xenografted with A375M tumor cells and received tracer injection at day 0. For blocking studies huNOG mice 
received a 10- fold excess of unlabeled pembrolizumab (huNOG excess). As a control for non- specific uptake huNOG mice 
were injected with 89Zr- IgG4. PET imaging performed on day 7 post injection (pi). (A) In vivo PET examples (maximum intensity 
projections) at day 7 pi showing uptake in tumor (T), axillary lymph nodes (LN), liver (L) and spleen (S). (B) In vivo uptake of 
89Zr- pembrolizumab in spleen, lymph nodes (axillary), liver and tumor, at day 7 pi. Uptake is expressed as SUVmean. (C) Ex vivo 
biodistribution of 89Zr- pembrolizumab in humanized NOG mice. Uptake is expressed as mean radioactivity per gram tissue, 
adjusted for total body weight (SUVmean ex vivo). Data expressed as median±IQR *p≤0.05. BAT, brown adipose tissue; huNOG, 
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89Zr- pembrolizumab spleen uptake in huNOG mice 
was blocked by the addition of a 10- fold excess unlabeled 
pembrolizumab (SUVmean 30.5, IQR 15.8 to 67.7 versus 
SUVmean 5.1, IQR 4.3 to 7.0, p=0.032) (figure 1B,C). 
Uptake in other lymphoid organs and liver was also 
reduced by addition of unlabeled mAb dose, whereas 
uptake in non- lymphoid tissues was unaffected (online 
supplemental table S3). Tracer activity in blood pool was 
increased by addition of unlabeled mAb (SUVmean 0.1, 
IQR 0.0 to 1.8 to SUVmean 2.2, IQR 1.4 to 7.4), but uptake 
in tumor did not change.
Autoradiography confirmed PET imaging results on 
a macroscopic level, showing high uptake in spleens of 
huNOG mice compared with spleens of mice that received 
an additional unlabeled pembrolizumab dose (figure 3). 
Furthermore, comparable tumor uptake was found for 
different dose groups. IHC analysis on spleen and lymph 
node tissue of huNOG mice revealed that PD-1, CD3 and 
CD8 positive cells were present. CD3 and CD8 cells were 
also present in tumor tissue of huNOG mice (figure 2), 
however, PD-1 staining of these tumors was negative.
89Zr- pembrolizumab biodistribution in NOG control 
mice clearly showed a different pattern than in huNOG 
mice, with high uptake in liver (SUVmean 16.9, IQR 5.1 
to 26.2) and spleen (SUVmean 49.6, IQR 16.6 to 135.6), 
whereas 89Zr- pembrolizumab tumor uptake in NOG mice 
was similar to huNOG mice (SUVmean 9.3, IQR 4.5 to 15.7 
vs SUVmean 5.1, IQR 3.3 to 8.9) (online supplemental 
figure S3). High 89Zr- pembrolizumab spleen uptake 
in this model may be unexpected, since limited T- cells 
are present in NOG mice (online supplemental figure 
Figure 2 IHC analysis of spleen, mesenteric lymph node and tumor tissue humanized NOG mice. Formalin- fixed and paraffin 
embedded tissue blocks where cut into slices of 4 µM and stained for PD-1, CD3 and CD8 (40x). H&E staining served to analyze 
tissue viability and morphology (40x). Scalebar: 50 µm. IHC, immunohistochemical; PD-1, programmed cell death protein-1.
Figure 3 Autoradiography of spleen and tumor tissue 
humanized NOG mice (huNOG). Formalin- fixed and paraffin 
embedded tissue blocks where cut into slices of 4 µM. These 
slices were exposed to a phosphor imaging screen for 72 
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S3). However, high spleen uptake in severely immuno-
compromised mice has been described previously and 
is potentially Fcγ receptor- mediated.23 24 32 Moreover, 
spleen weights in NOG mice were lower than in huNOG 
mice (NOG: 0.017 g±0.015 g; huNOG: 0.037 g±0.016 g, 
p=0.036), which resulted in higher tracer uptake 
expressed as %ID per gram spleen tissue for NOG mice. 
A low spleen weight may result from high radiosensitivity 
of NOG splenocytes, which can lead to toxicity.33
Critical steps in 89Zr-pembrolizumab manufacturing
The production processes for N- sucDf- pembrolizumab 
intermediate product and 89Zr- pembrolizumab for in vivo 
studies were modified to comply with GMP requirements. 
In the conjugation reaction, pH is increased from 4.5 to 
8.5, performed in small titration steps, as described earlier 
by Verel et al.30 During this pH transition, precipitation 
occurred at 6.5 to 7.0, which was re- dissolved at pH >7.5. 
No precipitation was observed when pH was changed 
abruptly, for example, by buffer exchange, to pH 8.5 
during conjugation and to pH 4.5 for removal of Fe(III). 
This indicates potential instability of pembrolizumab at 
pH 6.5 to 7.0. Formation of aggregates may be explained 
by the fact that pembrolizumab is an IgG4 type mAb, which 
forms non- classical disulfide bonds. In contrast, IgG1 type 
antibodies can only form classical disulfide bonds. There 
are many other determinants of antibody stability besides 
disulfide bond formation, however, this phenomenon was 
not seen previously with the radiolabeling of IgG1 type 
antibodies.31 33 34
Immunoreactivity was not affected when pembroli-
zumab showed precipitation during pH transition, 
demonstrated by comparable IRF for precipitated N- sucDf- 
pembrolizumab and for non- precipitated N- sucDf- 
pembrolizumab (online supplemental figure S4). 
However, it is unknown whether the pembrolizumab struc-
ture is modified by the formation of precipitates. There-
fore, the method for pH transition by buffer exchange was 
incorporated in the conjugation protocol for pembroli-
zumab. Production of clinical grade 89Zr- pembrolizumab 
was performed as previously described by Verel et al.30
89Zr-pembrolizumab GMP validation
Three consecutive batches of conjugated and radiola-
beled pembrolizumab were produced at clinical scale 
and complied with all release specifications (online 
supplemental tables S1 and S2), indicating that our 
process for manufacturing clinical grade 89Zr- pembroli-
zumab is consistent and robust. 89Zr- pembrolizumab 
was obtained with a specific activity of 37 MBq/mg and 
mean IRF of 1.35±0.6 (n=3). Stability studies revealed 
that N- sucDf- pembrolizumab remained compliant to 
release specifications up to 6 months storage at −80°C, 
therefore N- sucDf- pembrolizumab shelf- life was set at 6 
months. Stability studies are ongoing and shelf- life may 
be extended if future time points remain within spec-
ifications. Data obtained during process development 
and validation were used to compile the investigational 
medicinal product dossier (IMPD), which includes all 
information regarding quality control, production and 
validation of 89Zr- pembrolizumab. Based on this IMPD, 
89Zr- pembrolizumab has been approved by competent 
authorities for use in clinical studies.
DISCUSSION
This study reveals 89Zr- pembrolizumab whole- body distri-
bution in tumor- bearing huNOG mice established with a 
broad set of developed immune cells. Tumor uptake of 
89Zr- pembrolizumab was markedly lower than uptake in 
lymphoid tissues such as spleen, lymph nodes and bone 
marrow, but higher than uptake in other organs. Impor-
tantly, high uptake in lymphoid tissues could be reduced 
with a 10- fold excess of unlabeled pembrolizumab. 
This contrasts with 89Zr- pembrolizumab tumor uptake, 
which was not reduced by the addition of unlabeled 
pembrolizumab.
Our study nicely shows the in vivo behavior of 89Zr- pem-
brolizumab, which, apart from IgG pharmacokinetics 
determined by its molecular weight and Fc tail, is predom-
inantly driven by its affinity for PD-1 (Kd:~30 pM). The 
PD-1 cell surface receptor is primarily expressed on acti-
vated T- cells and pro B- lymphocytes, which are abun-
dantly present in our huNOG mouse model. Lymphocytes 
are highly concentrated in organs that are key players of 
the immune system: lymph nodes, spleen, thymus, bone 
marrow as well as tonsils, adenoid and Peyer’s patches. 
From our PET imaging and ex vivo biodistribution data, 
we learned that 89Zr- pembrolizumab distributed mainly 
to lymphoid organs, where PD-1 expressing immune cells 
are present.
89Zr- pembrolizumab showed relatively low and variable 
tumor uptake, however, this uptake could be visualized 
with PET imaging 7 days pi and was higher than in non- 
lymphoid tissues. We hypothesized there may be PD-1- 
mediated 89Zr- pembrolizumab tumor uptake, but we also 
found tumor uptake for 89Zr- IgG4, suggesting part of the 
89Zr- pembrolizumab tumor uptake is FcγR- mediated. In 
our mouse model, few PD-1 positive immune cells may 
have traveled to the tumor, thereby potentially limiting 
89Zr- pembrolizumab tumor uptake. Interestingly, the 
addition of unlabeled pembrolizumab did not influence 
tumor uptake. This is likely caused by substantial increase 
of 89Zr- pembrolizumab in blood pool as a direct conse-
quence of adding excess unlabeled pembrolizumab, 
warranting a continuous pembrolizumab supply to the 
tumor.
Ex vivo immunohistochemical analysis revealed CD3 
and CD8 positive lymphocytes were present in tumor, but 
limited PD-1- expression was found. Immune checkpoint 
protein expression status in tumor- infiltrating lympho-
cytes is highly dynamic.35 36 This so- called ‘immune 
phenotype’ depends on several factors, including tumor 
type, location and mutational burden. Our results indi-
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variation, 89Zr- pembrolizumab PET imaging is able to 
capture PD-1 dynamics in both tumor and healthy tissues.
Compared with earlier preclinical studies with radio-
labeled pembrolizumab in the hNSG model, we found 
higher 89Zr- pembrolizumab uptake in spleen and other 
lymphoid tissues.23 24 This likely reflects the presence of 
multiple hematopoietic cell lineages, including B- cells, 
T- cells, NK- cells, dendritic cells and monocytes, and thus 
higher PD-1 expression, in our huNOG model compared 
with the hNSG model. Molecular imaging studies with 
radiolabeled antibodies generally show distribution to 
the spleen. It also known that Fc/FcγR- mediated immu-
nobiology of the experimental mouse model plays a key 
role in the in vivo biodistribution and tumor targeting.33 
In our mouse model, we also observed 89Zr- IgG4 uptake in 
lymphoid tissues, indicating 89Zr- pembrolizumab uptake 
in these organs may have an FcγR- mediated component. 
For most radiolabeled antibodies without an immune 
target, spleen uptake in patients is ~5 %ID/kg.37 This 
supports the idea that, independent of their target, anti-
bodies often show distribution to the spleen. However, 
spleen uptake may be higher if PD-1 or PD- L1 is present.
Pembrolizumab has an IgG4κ backbone with a stabi-
lizing SER228PRO sequence alteration in the Fc- region 
to prevent the formation of half molecules. The IgG4 
backbone of pembrolizumab may slightly differ from the 
IgG4 control molecule that we used for our experiments, 
however, FcγR- binding affinity and kinetics of pembroli-
zumab appears to be very similar to IgG4.
38 We, therefore, 
consider the used IgG4 control molecule to provide a 
useful indication of the extent of FcγR- mediated uptake. 
In this respect, FcγR- mediated uptake may be present 
in the spleen but potentially also in liver and tumor, 
since these tissues demonstrate relatively high uptake of 
89Zr- IgG4.
PD-1 is predominantly expressed on activated T- cells 
while its ligand PD- L1 is expressed by a broader range of 
immune cells as well as tumor cells. It is therefore to be 
expected that biodistribution of antibody tracers targeting 
PD- L1 may deviate from the biodistribution results that 
we described here for 89Zr- pembrolizumab. In table 1, we 
presented an overview of preclinical imaging and biodis-
tribution studies using anti- PD-1 and anti- PD- L1 tracers. 
Data turned out to be highly variable, mostly focused on 
tumor and not on the immune system, and therefore 
not just comparable. From our results, we increasingly 
realize that it is extremely important for interpretation of 
these type of data to know the characteristics of the anti-
body (origin, cross- reactivity, Fc- backbone, target, target- 
affinity and dose), the animal model (mouse strain, age, 
immune status and tumor cell line) and time points, vari-
ables we detailed in the table.
As for preclinical studies, data on the distribution of 
PD-1 and PD- L1 targeting antibodies to lymphoid organs 
in patients is still limited. A clinical imaging study in 13 
patients demonstrated modest 89Zr- nivolumab spleen 
uptake of SUVmean 5.8±0.7, whereas uptake of this radiola-
beled antibody targeting PD-1 in other lymphoid tissues 
was not addressed.39 89Zr- atezolizumab (anti- PD- L1 anti-
body) imaging in 22 patients revealed spleen uptake with 
an SUVmean of 15. 
89Zr- atezolizumab also distributed to 
other lymphoid tissues and sites of inflammation, whereas 
uptake in non- lymphoid organs was low. The high spleen 
uptake could at least partly be explained by presence 
of PD- L1 in endothelial littoral cells of the spleen.40 To 
perceive what can be expected for 89Zr- pembrolizumab 
PET imaging in patients, how results may be interpreted 
and potentially translated to predicting response, knowl-
edge on which immune cells express PD-1 and where 
these cells are located in the human body is of utmost 
importance.
With our study, we validated the use of 89Zr- pembroli-
zumab PET imaging to evaluate PD-1- mediated uptake in 
tumor and immune tissues in a setting that allowed for 
comparing tracer uptake and whole tumor tissue analysis. 
To enable evaluation of 89Zr- pembrolizumab biodistribu-
tion in humans, we developed clinical grade 89Zr- pem-
brolizumab. Clinical 89Zr- pembrolizumab PET imaging 
in patients with melanoma and NSCLC before treatment 
with pembrolizumab is currently performed at our center 
( ClinicalTrials. gov Identifier NCT02760225), and may 
elucidate if tracer tumor uptake correlates to response 
and if uptake in healthy PD-1 expressing tissues correlates 
to toxicity.
CONCLUSION
We demonstrated the in vivo biodistribution of 89Zr- pem-
brolizumab in humanized mice, and found uptake in 
tumor with the highest uptake in the lymphoid system, 
reflecting the presence of PD-1. Insight in the in vivo 
behavior and biodistribution of immune checkpoint 
targeting monoclonal antibodies might aid in better 
understanding immune checkpoint inhibition therapy 
and could potentially help explaining variation in 
response as well as potential toxicity due to uptake in 
healthy (immune) tissues.
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